Catch up on the essentials
- AstraZeneca PLC disclosed on September 18, 2026 that Chief Executive Officer Pascal Soriot bought 60,000 ordinary shares at £121.02 per share on September 14, 2026, via the London Stock Exchange.
- The transaction was announced as a foreign-issuer current report on Form 6-K, the standard U.S.
- At £121.02 per share, the purchase values the transaction at roughly £7.26 million before any currency conversion, making it a notable open-market accumulation by the company's chief executive.
Selected from this article · 2026-09-19
Read on for the full pictureSoriot's open-market purchase on the LSE
AstraZeneca PLC disclosed on September 18, 2026 that Chief Executive Officer Pascal Soriot bought 60,000 ordinary shares at £121.02 per share on September 14, 2026, via the London Stock Exchange. The shares carry a nominal value of US$0.25 each, and the purchase was reported to the company on September 16, 2026 through a Person Discharging Managerial Responsibilities (PDMR) notification under the UK Market Abuse Regulation.
Disclosure routed through a Form 6-K filing
The transaction was announced as a foreign-issuer current report on Form 6-K, the standard U.S. Securities and Exchange Commission filing mechanism by which AstraZeneca, listed on the London, Stockholm and New York stock exchanges under the ticker AZN, notifies the market of PDMR share dealings as required by the EU Market Abuse Regulation as it forms part of UK law. The filing carried neutral sentiment per the source's automated impact assessment and did not list any positive or negative disclosures.
Price and scale of the CEO buy
At £121.02 per share, the purchase values the transaction at roughly £7.26 million before any currency conversion, making it a notable open-market accumulation by the company's chief executive. Such insider purchases are recorded in real time and are made available to investors alongside any subsequent PDMR dealings.
Interpretive context from the filing
Source commentary frames the purchase as a confidence signal, noting that significant open-market buying by a CEO is often read by investors as an indicator of faith in the company's future prospects. That framing originates from the news outlet's analysis rather than from any company statement, and it does not reflect management's own forward-looking guidance.
Next verifiable milestone
The next material datapoint for investors will be AstraZeneca's subsequent PDMR notifications, which would disclose any further insider dealings by Soriot or other senior managers under the same UK Market Abuse Regulation framework.
Share this article
